Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial

Overview of attention for article published in Arthritis Research & Therapy, May 2015

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 39,953 followers.

RT @emiliomonteb: Cost-effectiveness of abatacept, rituximab, and TNFi after previous failure with TNFi in rheumatoid arthritis https://t.c…

RT @emiliomonteb: Cost-effectiveness of abatacept, rituximab, and TNFi after previous failure with TNFi in rheumatoid arthritis https://t.c…

Cost-effectiveness of abatacept, rituximab, and TNFi after previous failure with TNFi in rheumatoid arthritis https://t.co/vuI82yvxMZ

139TNFi failures switched to RTX, ABA, other TNFi- all equally effective. 80/139 cont Rx@1yr. RTX most cost effective http://t.co/zqJlwjJlNY

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.